Masini, G., Graham, F. J., Pellicori, P. , Cleland, J. G.F. , Cuthbert, J. J., Kazmi, S., Inciardi, R. M. and Clark, A. L. (2022) Criteria for iron deficiency in patients with heart failure. Journal of the American College of Cardiology, 79(4), pp. 341-351. (doi: 10.1016/j.jacc.2021.11.039) (PMID:35086656)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
259126.pdf - Published Version Available under License Creative Commons Attribution. 1MB |
Abstract
Background: Guidelines on heart failure (HF) define iron deficiency (ID) as a serum ferritin <100 ng/mL or, when 100-299 ng/mL, a transferrin saturation (TSAT) <20%. Inflammation (common in HF) may hinder interpretation of serum ferritin. Objectives: This study sought to investigate how different definitions of ID affect its prevalence and relationship to prognosis in ambulatory patients with chronic HF. Methods: Prevalence, relationship with patients’ characteristics, and outcomes of various ID definitions were evaluated among patients with HF referred to a regional clinic (Hull LifeLab) from 2001 to 2019. Results: Of 4,422 patients with HF (median age 75 years [range: 68-82 years], 60% men, 32% with reduced left ventricular ejection fraction), 46% had TSAT <20%, 48% had serum iron ≤13 μmol/L, 57% had serum ferritin <100 ng/mL, and 68% fulfilled current guideline criteria for ID, of whom 35% had a TSAT >20%. Irrespective of definition, ID was more common in women and those with more severe symptoms, anemia, or preserved ejection fraction. TSAT <20% and serum iron ≤13 μmol/L, but not guideline criteria, were associated with higher 5-year mortality (HR: 1.27; 95% CI: 1.14-1.43; P < 0.001; and HR: 1.37; 95% CI: 1.22-1.54; P < 0.001, respectively). Serum ferritin <100 ng/mL tended to be associated with lower mortality (HR: 0.91; 95% CI: 0.81-1.01; P = 0.09). Conclusions: Different definitions of ID provide discordant results for prevalence and prognosis. Definitions lacking specificity may attenuate the benefits of intravenous iron observed in trials while definitions lacking sensitivity may exclude patients who should receive intravenous iron. Prespecified subgroup analyses of ongoing randomized trials should address this issue.
| Item Type: | Articles |
|---|---|
| Additional Information: | Drs Pellicori and Cleland are supported by the British Heart Foundation Centre of Research Excellence (RE/18/6/34217). |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Masini, Dr Gabriele and Graham, Dr Fraser and Cleland, Professor John and Pellicori, Dr Pierpaolo |
| Authors: | Masini, G., Graham, F. J., Pellicori, P., Cleland, J. G.F., Cuthbert, J. J., Kazmi, S., Inciardi, R. M., and Clark, A. L. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > General Practice and Primary Care College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
| Journal Name: | Journal of the American College of Cardiology |
| Publisher: | Elsevier |
| ISSN: | 0735-1097 |
| ISSN (Online): | 1558-3597 |
| Published Online: | 24 January 2022 |
| Copyright Holders: | Copyright © 2022 The Authors |
| First Published: | First published in Journal of the American College of Cardiology 79(4):341-351 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information